IMU Biosciences Completes $53 Million Series A Fundraising

IMU Biosciences, decoding the immune system with unprecedented resolution and scale to transform how we understand, diagnose, and treat disease, led by Adam Laing, Mario Cantero, John Baker, and Thomas Hayday, has successfully brought its Series A to over $53 million (£40 million) in an oversubscribed financing round, co-led by IQ Capital and Molten Ventures, and supported by The British Business Bank, and Meltwind alongside existing investors. 

Building a Comprehensive Map of the Human Immune System.

IMU has developed one of the world’s largest immune datasets, containing samples from more than 25,000 individuals and combining extensive patient data with population-scale clinical information. Using multi-omic analysis and proprietary machine learning models, the platform can generate over 100 million immune-related data points from a single blood sample, creating a detailed view of immune system activity at clinical scale.

The company is working to establish a standardized approach to immune profiling that could improve disease understanding, enable more precise treatment selection, monitor disease progression, and help predict patient responses to therapy.

Having raised a total of $60 million (£45 million) to date, IMU will use the new funding to expand operations, enhance its clinical platform and infrastructure, and advance several key clinical programs. These include stem cell transplantation, solid organ transplantation, and the MANIFEST consortium, a UK-based research initiative focused on understanding patient responses to cancer immunotherapies.

Advancing a Data-Driven Understanding of the Immune System.

According to John Baker, the funding will support the expansion of IMU’s operations and platform while accelerating the deployment of its immune profiling technology across clinical programs.

He noted that, despite the immune system’s central role in human health, much of its complexity remains poorly understood due to limitations in existing analytical tools. By combining one of the world’s largest immune datasets with proprietary computational and biological technologies, IMU aims to uncover new biological insights, support the development of targeted therapies, and provide clinicians with more precise tools for diagnosing and treating disease.

Investors See Immune Profiling as a Foundation for Precision Medicine.

According to Inga Deakin, IMU’s combination of deep immune profiling and AI has the potential to become a transformative platform for precision medicine. She highlighted the company’s progress since Molten Ventures’ initial investment in 2024, citing both strong execution and continued development of its technology.

Investors believe that the ability to analyze the immune system at unprecedented resolution could improve how treatments are matched to individual patients, helping clinicians make more informed decisions across a wide range of diseases. The participation of new investors was also described as further validation of IMU’s platform and long-term vision.

Backing the Next Phase of Immune Intelligence.

According to Alex Wilson, IMU’s combination of a large-scale immune dataset and proprietary machine learning capabilities positions the company to unlock new insights from health data and advance precision medicine.

As a co-lead investor in the round, IQ Capital sees significant potential in IMU’s ability to generate clinically relevant insights that can support better decision-making, improve patient outcomes, and expand understanding of the immune system as the company continues to scale its platform and technology.

A Foundational Platform for Immune-Driven Medicine.

According to Carmine Circelli, IMU combines large-scale proprietary immune data with deep biological expertise to create a platform capable of delivering an unprecedented view of the human immune system.

He noted that this capability has the potential to reshape how diseases are understood, diagnosed, and treated, while supporting the development of more precise and effective therapies. The investment reflects confidence in IMU’s ability to scale its platform in the UK and translate its scientific insights into tangible clinical benefits for patients.